Cisen Pharmaceutical Co (SHSE:603367) Accounts Payable: ¥605 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603367 Cisen Pharmaceutical Co Ltd SHSE:603367
68 GF Score
Price ¥14.90
GF Value ¥14.45
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Cisen Pharmaceutical Co Accounts Payable?

Cisen Pharmaceutical Co SHSE:603367 -0.67% 68 Accounts Payable is ¥605 Mil as of Jun. 2026. GuruFocus rates SHSE:603367 with a GF Score™ of 68/100 and a GF Value™ of ¥14.45 (Fairly Valued). The stock has 3 warning signs investors should review.

Cisen Pharmaceutical Co's Accounts Payable for the quarter that ended in Jun. 2026 was ¥605 Mil.

Cisen Pharmaceutical Co's quarterly Accounts Payable declined from Dec. 2025 (¥620 Mil) to Mar. 2026 (¥579 Mil) but then increased from Mar. 2026 (¥579 Mil) to Jun. 2026 (¥605 Mil).

Cisen Pharmaceutical Co's annual Accounts Payable increased from Dec. 2023 (¥468 Mil) to Dec. 2024 (¥549 Mil) and increased from Dec. 2024 (¥549 Mil) to Dec. 2025 (¥620 Mil).

Cisen Pharmaceutical Co Accounts Payable Related Terms

Cisen Pharmaceutical Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cisen Pharmaceutical Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cisen Pharmaceutical Co Accounts Payable Chart

Cisen Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 434.97 459.71 468.01 549.49 620.31

Cisen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 685.21 711.15 620.31 578.77 605.02
SHSE:603367
68GF Score
Cisen Pharmaceutical Co Ltd SHSE:603367
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cisen Pharmaceutical Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥605 Mil mean?
Cisen Pharmaceutical Co (SHSE:603367) has a Accounts Payable of ¥605 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cisen Pharmaceutical Co and its competitors.
Is Cisen Pharmaceutical Co's Accounts Payable too high?
Cisen Pharmaceutical Co's current Accounts Payable is ¥605 Mil. Overall, Cisen Pharmaceutical Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cisen Pharmaceutical Co's Accounts Payable compare to ZTS?
Cisen Pharmaceutical Co's Accounts Payable of ¥605 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cisen Pharmaceutical Co and its competitors. Cisen Pharmaceutical Co's current Accounts Payable is ¥605 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cisen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Cisen Pharmaceutical Co (SHSE:603367) is currently considered Fairly Valued. The stock's GF Value™ is ¥14.45, compared to a current price of ¥14.90 — trading 3.1% above its estimated fair value. The current Accounts Payable is ¥605 Mil. Cisen Pharmaceutical Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cisen Pharmaceutical Co (SHSE:603367), the current Accounts Payable is ¥605 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cisen Pharmaceutical Co (SHSE:603367) Overvalued in 2026?

Based on GuruFocus' analysis, Cisen Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥14.90 is trading 3.1% above its estimated GF Value™ of ¥14.45. GuruFocus considers Cisen Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603367:

  • Accounts Payable: ¥605 Mil
  • GF Value™: ¥14.45 vs. price of ¥14.90 (3.1% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cisen Pharmaceutical Co Business Description

Address Tongji Sci-tech Industrial Park, High-tech Industrial Development Zone, Shandong, Jining, CHN, 272073
Cisen Pharmaceutical Co Ltd is the pharmaceutical company in China. The company's main business is the development, production and sales of pharmaceutical products, mainly in the production of chemical preparations. Its product offering includes chemical drug preparations such as liver disease drug, antitumor and auxiliary drugs, nutrition preparation, cardiovascular class, antibiotics, sedation anaesthesia snooze, digestive system agents; and healthcare products.
68GF Score

Get the complete analysis for SHSE:603367

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.90
Price
¥14.45
GF Value